Successful debulking of plurihormonal pituitary macroadenoma with long‐acting pasireotide and dopamine agonist combination therapy
Key Clinical Message Long‐acting pasireotide and bromocriptine provided biochemical control of growth hormone and prolactin in a patient with plurihormonal pituitary macroadenoma, allowing near‐complete tumor excision while restoring pituitary function and avoiding adjunctive radiotherapy. Pasireoti...
Main Authors: | Terri W. Jerkins, Randy K. Jerkins, Robbi Franklin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-03-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.1961 |
Similar Items
-
Pasireotide: A new option for treatment of acromegaly
by: Filiz Eksi Haydardedeoglu, et al.
Published: (2020-06-01) -
Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
by: Feun LG, et al.
Published: (2018-01-01) -
Successful Control of Hypoglycemia with Pasireotide LAR in a Patient with Inappropriate Insulin Secretion
by: Rouland A, et al.
Published: (2021-02-01) -
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
by: Mônica R Gadelha, et al.
Published: (2020-12-01) -
Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis
by: Alessandro Mondin, et al.
Published: (2022-07-01)